A citation-based method for searching scientific literature

David Z I Cherney, Francesco Cosentino, Samuel Dagogo-Jack, Darren K McGuire, Richard Pratley, Robert Frederich, Mario Maldonado, Chih-Chin Liu, Jie Liu, Annpey Pong, Christopher P Cannon. Clin J Am Soc Nephrol 2021
Times Cited: 2







List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
560
100

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
100

Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
David Z I Cherney, Bernard Charbonnel, Francesco Cosentino, Samuel Dagogo-Jack, Darren K McGuire, Richard Pratley, Weichung J Shih, Robert Frederich, Mario Maldonado, Annpey Pong,[...]. Diabetologia 2021
20
100

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
736
50

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D Barrett, Michele Weidner-Wells, Hsiaowei Deng, David R Matthews,[...]. Lancet Diabetes Endocrinol 2018
247
50

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
Faiez Zannad, João Pedro Ferreira, Stuart J Pocock, Cordula Zeller, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Sibylle Jenny Hauske, Martina Brueckmann, Egon Pfarr,[...]. Circulation 2021
31
50

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
Christoph Wanner, Hiddo J L Heerspink, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Stefan Hantel, Hans-Juergen Woerle, Uli C Broedl, Maximilian von Eynatten,[...]. J Am Soc Nephrol 2018
68
50

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
289
50

GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.
Lesley A Inker, Hiddo J L Heerspink, Hocine Tighiouart, Andrew S Levey, Josef Coresh, Ron T Gansevoort, Andrew L Simon, Jian Ying, Gerald J Beck, Christoph Wanner,[...]. J Am Soc Nephrol 2019
53
50

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
Pardeep S Jhund, Scott D Solomon, Kieran F Docherty, Hiddo J L Heerspink, Inder S Anand, Michael Böhm, Vijay Chopra, Rudolf A de Boer, Akshay S Desai, Junbo Ge,[...]. Circulation 2021
48
50

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
50


Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study.
Anna Solini, Giuseppe Penno, Enzo Bonora, Cecilia Fondelli, Emanuela Orsi, Maura Arosio, Roberto Trevisan, Monica Vedovato, Mauro Cignarelli, Francesco Andreozzi,[...]. Diabetes Care 2012
81
50

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.
Aidin Rawshani, Araz Rawshani, Stefan Franzén, Björn Eliasson, Ann-Marie Svensson, Mervete Miftaraj, Darren K McGuire, Naveed Sattar, Annika Rosengren, Soffia Gudbjörnsdottir. N Engl J Med 2017
482
50

Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study.
Basilio Pintaudi, Alessia Scatena, Gabriella Piscitelli, Vera Frison, Salvatore Corrao, Valeria Manicardi, Giusi Graziano, Maria Chiara Rossi, Marco Gallo, Domenico Mannino,[...]. Cardiovasc Diabetol 2021
6
50

Comparative effectiveness of dapagliflozin vs DPP-4 inhibitors on a composite endpoint of HbA1c, body weight and blood pressure reduction in the real world.
Mario Luca Morieri, Agostino Consoli, Giorgio Sesti, Francesco Purrello, Angelo Avogaro, Gian Paolo Fadini. Diabetes Metab Res Rev 2021
5
50

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.
Paola Fioretto, Stefano Del Prato, John B Buse, Ronald Goldenberg, Francesco Giorgino, Daniel Reyner, Anna Maria Langkilde, C David Sjöström, Peter Sartipy. Diabetes Obes Metab 2018
65
50

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
Hiddo J L Heerspink, Avraham Karasik, Marcus Thuresson, Cheli Melzer-Cohen, Gabriel Chodick, Kamlesh Khunti, John P H Wilding, Luis Alberto Garcia Rodriguez, Lucia Cea-Soriano, Shun Kohsaka,[...]. Lancet Diabetes Endocrinol 2020
92
50


Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurray. Lancet Diabetes Endocrinol 2019
399
50

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
242
50

Resurgence in Diabetes-Related Complications.
Edward W Gregg, Israel Hora, Stephen R Benoit. JAMA 2019
89
50

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
Andrew S Levey, Ron T Gansevoort, Josef Coresh, Lesley A Inker, Hiddo L Heerspink, Morgan E Grams, Tom Greene, Hocine Tighiouart, Kunihiro Matsushita, Shoshana H Ballew,[...]. Am J Kidney Dis 2020
105
50

Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.
M Monami, I Iacomelli, N Marchionni, E Mannucci. Nutr Metab Cardiovasc Dis 2010
140
50

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
50

Changes in diabetes-related complications in the United States, 1990-2010.
Edward W Gregg, Yanfeng Li, Jing Wang, Nilka Rios Burrows, Mohammed K Ali, Deborah Rolka, Desmond E Williams, Linda Geiss. N Engl J Med 2014
925
50

Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study.
Gian Paolo Fadini, Anna Solini, Maria Laura Manca, Giuseppe Penno, Adriano Gatti, Roberto Anichini, Stefano Del Prato, Angelo Avogaro. Diabetes Obes Metab 2019
20
50

GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.
Andrew S Levey, Lesley A Inker, Kunihiro Matsushita, Tom Greene, Kerry Willis, Edmund Lewis, Dick de Zeeuw, Alfred K Cheung, Josef Coresh. Am J Kidney Dis 2014
279
50

Diabetes with early kidney involvement may shorten life expectancy by 16 years.
Chi Pang Wen, Chia Hsuin Chang, Min Kuang Tsai, June Han Lee, Po Jung Lu, Shan Pou Tsai, Christopher Wen, Chien Hua Chen, Chih Wen Kao, Chwen Keng Tsao,[...]. Kidney Int 2017
48
50


All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database.
Konstantinos A Toulis, Brian H Willis, Tom Marshall, Balachadran Kumarendran, Krishna Gokhale, Sandip Ghosh, G Neil Thomas, Kar Keung Cheng, Parth Narendran, Wasim Hanif,[...]. J Clin Endocrinol Metab 2017
48
50



Observational studies: going beyond the boundaries of randomized controlled trials.
Wenying Yang, Alexey Zilov, Pradana Soewondo, Ole Molskov Bech, Fawzia Sekkal, Philip D Home. Diabetes Res Clin Pract 2010
85
50


Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson,[...]. Circulation 2017
464
50

Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes.
Yan Xie, Benjamin Bowe, Andrew K Gibson, Janet B McGill, Geetha Maddukuri, Ziyad Al-Aly. J Am Heart Assoc 2021
4
50


A view on the quality of diabetes care in Italy and the role of Diabetes Clinics from the 2018 ARNO Diabetes Observatory.
Enzo Bonora, Salvatore Cataudella, Giulio Marchesini, Roberto Miccoli, Olga Vaccaro, Gian Paolo Fadini, Nello Martini, Elisa Rossi. Nutr Metab Cardiovasc Dis 2020
9
50

Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.
Toshiharu Ninomiya, Vlado Perkovic, Bastiaan E de Galan, Sophia Zoungas, Avinesh Pillai, Meg Jardine, Anushka Patel, Alan Cass, Bruce Neal, Neil Poulter,[...]. J Am Soc Nephrol 2009
595
50

Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events.
Yan Xie, Benjamin Bowe, Andrew K Gibson, Janet B McGill, Yan Yan, Geetha Maddukuri, Ziyad Al-Aly. Diabetes Care 2020
15
50

The Importance and Role of Multiple Risk Factor Control in Type 2 Diabetes.
Caroline Holm Nørgaard, Mitra Mosslemi, Christina J-Y Lee, Christian Torp-Pedersen, Nathan D Wong. Curr Cardiol Rep 2019
5
50

Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality.
Josef Coresh, Tanvir Chowdhury Turin, Kunihiro Matsushita, Yingying Sang, Shoshana H Ballew, Lawrence J Appel, Hisatomi Arima, Steven J Chadban, Massimo Cirillo, Ognjenka Djurdjev,[...]. JAMA 2014
541
50

Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes.
Salvatore De Cosmo, Maria Chiara Rossi, Fabio Pellegrini, Giuseppe Lucisano, Simonetta Bacci, Sandro Gentile, Antonio Ceriello, Giuseppina Russo, Antonio Nicolucci, Carlo Giorda,[...]. Nephrol Dial Transplant 2014
37
50

Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials.
David Z I Cherney, Samuel Dagogo-Jack, Darren K McGuire, Francesco Cosentino, Richard Pratley, Weichung J Shih, Robert Frederich, Mario Maldonado, Jie Liu, Shuai Wang,[...]. Clin Cardiol 2021
2
50

Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.
Björn Pasternak, Viktor Wintzell, Mads Melbye, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Henrik Svanström,[...]. BMJ 2020
29
50

Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy.
Misghina Weldegiorgis, Dick de Zeeuw, Liang Li, Hans-Henrik Parving, Fan Fan Hou, Giuseppe Remuzzi, Tom Greene, Hiddo J L Heerspink. Am J Kidney Dis 2018
36
50

Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study.
Giuseppe Penno, Anna Solini, Emanuela Orsi, Enzo Bonora, Cecilia Fondelli, Roberto Trevisan, Monica Vedovato, Franco Cavalot, Olga Lamacchia, Marco Scardapane,[...]. Diabetologia 2018
41
50


Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Deepak L Bhatt, Michael Szarek, Bertram Pitt, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Silvio E Inzucchi, Mikhail N Kosiborod,[...]. N Engl J Med 2021
150
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.